Objective: We addressed the role of platelets in mediating CNS inflammation in EAE.
M ultiple sclerosis (MS) is an inflammatory degenerative disease of the central nervous system (CNS). [1] [2] [3] [4] [5] MS and its mouse counterpart, experimental autoimmune encephalomyelitis (EAE), are initiated by infiltration of the neuronal tissue by T-cells autoreactive to antigens of the myelin sheath. 6 -9 The subsequent breakdown of the blood-brain barrier (BBB) facilitates the recruitment of further inflammatory effector cells such as mononuclear cells and macrophages 1, 10 and the activation of resident inflammatory microglial cells that contribute to the development of CNS lesions. 11 Inhibiting the inflammatory response is a promising therapeutic approach in EAE and MS. 1, 9 For instance, leukocyte integrins or their endothelial counterreceptors that contribute to inflammatory cell recruitment represent therapeutic targets in EAE and MS. 9, 12, 13 sites of vascular endothelial injury. 14 -17 Several platelet adhesion receptors, such as the glycoprotein (GP) VI, the integrin GPIIbIIIa (also designated as ␣IIb␤3-integrin or CD41/CD61-integrin; CD indicates cluster of differentiation), or the GPIb/IX/V complex, mediate platelet adhesion or aggregation. 18 Platelet-derived chemokines and cytokines can trigger inflammation in a paracrine fashion, whereas the direct adhesive interactions of platelets with endothelial cells and inflammatory cells promote leukocyte recruitment to the inflamed tissue. Distinct platelet adhesion receptors have been implicated in these processes, including P-selectin, junctional adhesion molecule-C, or GPIb. The latter receptor consists of the GPIb␣ and GPIb␤ chains and is a component of the GPIb/IX/V complex that acts as the von Willebrand Factor (vWF) receptor mediating platelet adhesion to the inflamed endothelial surface and the subendothelial matrix, whereas the interaction of GPIb with the leukocyte integrin Mac-1 promotes leukocyte/platelet interactions and thereby inflammatory cell recruitment. Platelets are thus recognized as an important link between hemostasis and inflammation. 14,15,19 -27 A recent microarray approach analyzing differentially expressed genes in plaques from patients with MS revealed an upregulation of the message of the platelet-specific GPIIb in patients with chronic demyelinating disease. 28 Furthermore, a recent report demonstrated increased activation of platelets in the peripheral blood from patients with MS. 29 These observations prompted us to investigate whether platelets could play a role in the pathogenesis of EAE. The present work demonstrates for the first time that platelets constitute a substantial component of the inflammatory response in the course of EAE by promoting the inflammatory response in the CNS. Targeting platelets or their interactions with inflammatory cells may thus represent a novel therapeutic approach to ameliorate inflammatory lesions in MS.
Methods
An expanded Methods section is available in the online Data Supplement.
"Reagents," "Induction of EAE in Mice," "Intravital Microscopy After EAE Induction," "Isolation of Primary Mouse Cells," "Adhesion Assays," "Reverse Transcriptase--PCR and Real-Time RT-PCR," "RNA Isolation and Microarray Analysis," "Detection of Platelets in Human MS Tissue," and "Data Presentation and Statistics" are described in detail in the Online Supplement.
Results

Platelets Are Present in the CNS of Mice After Induction of EAE and in Human MS Lesions
To address a potential contribution of platelets to the inflammatory lesions of EAE, we first assessed for the presence of platelets in the CNS after EAE induction. EAE was induced in mice using myelin oligodendrocyte glycoprotein (MOG). At different time points after EAE induction, we analyzed the inflamed spinal cords for the presence of platelets as assayed by the detection of the platelet-specific CD41 (GPIIb) and GPIb (CD42b). Before euthanizing the mice and extracting the spinal cords, mice were perfused to efficiently remove circulating blood including circulating platelets, thus allowing for the assessment of only tissue-associated platelets or platelets permanently adherent on the endothelium of the inflamed CNS vessels. First, as compared with noninflamed spinal cords, we found elevated levels of CD41 mRNA and GPIb mRNA in the inflamed spinal cords of mice on day 21 after EAE induction, representing the effector phase of the disease ( Figure 1A and 1B). These results are in line with a previous report that demonstrated an upregulation of CD41 mRNA in chronic human MS lesions. 28 Second, using immunohistochemistry with an antibody for the platelet-specific Figure 1 . Platelets are present in spinal cord during EAE. A, B, C, and D, EAE was induced in female wild-type mice, and spinal cords were collected after extensive systemic perfusion with saline on day 0 and day 21 after immunization. On day 0 or day 21, samples were analyzed for mRNA levels of plateletspecific CD41 (A) or CD42b (GPIb␣) (B). Data are meanϮSEM (nϭ4 -5) and are shown as percent of control. The ratio of CD41 mRNA/actin mRNA or GPIb/ actin mRNA on day 0 represents the 100% control. *PϽ0.05. C and D, Tissues from mice on day 0 and day 21 after EAE induction were analyzed for the plateletspecific marker CD42 (GPIb) (dark blue) and the microglial marker Iba-1 (brown) by immunohistochemistry. Arrows indicate platelets. Scale bar (C): 100 m; scale bar (D): 50 m.
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blood-brain barrier GPIb, we could visualize platelets in inflamed spinal cords, in parts localizing in inflamed areas containing activated microglial cells, which were stained by the marker Iba-1 ( Figure 1C and 1D). Furthermore, the presence of platelets in inflamed spinal cords was assessed by Western blot analysis for platelet specific GPIIb. Platelets were detectable at the effector phase of the disease (ie, after clinical disease onset), whereas no platelets were found in noninflamed spinal cord tissues (Online Figure I ). In addition to inflamed spinal cords, platelets were detectable in inflamed brain sections of mice subjected to EAE (Online Figure I) . Moreover, we assessed for the presence of platelets in lesions from human MS patients. Four cases of patients with MS were analyzed. All cases displayed active demyelination plaques including perivascular chronic inflammatory infiltrates composed of lymphocytes and plasma cells, macrophage infiltration, myelin breakdown with relative preservation of axons, and gliosis. Positive platelet staining with anti-human CD42b was observed in vessels and capillaries, in areas of hemorrhage, and in the extracellular space, which could represent potentially extravasated platelets. Normal adjacent brain areas as well as sections from normal human brain tissue displayed minimal to no positive platelet staining. Sections stained using IgG control antibody were also negative ( Figure 2 ). Furthermore, a chronic active plaque from a 54-year-old female patient with clinically definite MS 30, 31 (from a different center fulfilling the criteria of chronic active lesions) 32 also displayed abundant platelets as assessed by GPIb staining (Online Figure I) .
Platelets Contribute to EAE Pathogenesis
Because platelets were present in the inflamed CNS after EAE induction, we then examined their impact on EAE by using pharmacological depletion of platelets. Efficient platelet depletion was achieved with an intraperitoneal injection of rabbit anti-mouse platelet serum (depletion of Ͼ97% at 24 hours after injection) (Online Figure II) , as previously described. 24 Platelet depletion lasted for at least 72 hours (data not shown). The platelet-depleting serum did not alter the number of circulating total leukocytes (Online Figure II) , as previously described. 33 Neither control nor platelet-depleting serum had any immunestimulatory effects, as assessed by tumor necrosis factor-␣ and C3 levels in the serum of mice (data not shown).
We performed platelet depletion either in the immunization phase or in the inflammatory effector phase of EAE, when clinical disease is evident. In the former case, mice received an intraperitoneal injection of platelet-depleting serum or control serum at 2 different time points, on days 2 and 6, whereas in the latter case, mice received platelet-depleting serum or control serum on days 12 and 16 after immunization (day 12 represents the average begin of clinical disease in EAE, that is, the effector phase). Whereas platelet depletion during the immunization phase of disease did not affect EAE development ( Figure 3A) , depletion of platelets resulted in a significant and persistent reduction in EAE disease severity 2 days after application of the depleting agent ( Figure 3B ). Consistent with reduced EAE disease severity on platelet depletion in the effector phase, we found ameliorated loss of axonal integrity, as assessed by axonal staining using the neurofilament-200 (NF-200) as a marker, in mice that received the platelet-depleting serum as compared with mice receiving control serum (Online Figure III) . Moreover, reduced demyelination was also found on platelet depletion as analyzed by Luxol fast blue staining of the spinal cords (Online Figure III) . Taken together, our findings suggest a role of platelets in the effector phase of EAE, whereas platelets do not interfere with the immunization phase of EAE.
Platelets Contribute to the Inflammatory Response During EAE Pathogenesis
The data that platelet depletion during the effector phase of EAE reduced EAE severity indicated that platelets contribute to inflammation in the course of EAE. Indeed, inflammation in EAE was blunted on platelet depletion on days 12 and 16 after immunization, as evidenced by studying different components of the inflammatory response of EAE. First, activation of resident microglial cells is a marker of the inflammatory response in the course of EAE, and activated microglia contribute to CNS inflammation and myelin sheath lesions. 11 Interestingly, we observed a significant reduction of microgliosis area in the inflamed spinal cord on platelet depletion in mice as compared with control mice (Figure 4A and 4B) . Second, we performed microarray analysis of the inflamed spinal cords from EAE mice that were treated with control or platelet-depleting serum. Several inflammatory and immune factors and pathways were significantly downregulated in the inflamed spinal cords on platelet depletion. Selected proinflammatory factors such as cytokines, chemokines, or adhesion molecules that were significantly downregulated in the spinal cords on platelet depletion are summarized in Online Table I . We confirmed the downregulation of selected proinflammatory factors (the chemokines CCL-2, CCL-5, the chemokine receptor CXCR-4, the cytokine IL-1␤, the macrophage marker CD68, and the adhesion molecule ICAM-1) in the spinal cord on platelet depletion by real-time PCR analysis ( Figure 4C ).
Third, platelets contributed to inflammatory cell recruitment in the course of EAE. We observed decreased accumulation of inflammatory cells to the inflamed CNS on platelet depletion. In particular, mice treated with the plateletdepleting or the control serum on days 12 and 16 after immunization were euthanized on day 21. Immediately before euthanasia, mice were perfused with saline to remove circulating cells, the inflamed spinal cords were extracted, leukocytes were isolated, and their total number was counted. Flow cytometry analysis of the leukocyte populations isolated from inflamed spinal cords was performed for CD45 and CD11b, and we assessed the numbers of CD45 high CD11b ϩ cells representing recruited monocytes/macrophages. 34 -36 On platelet depletion, a significant decrease in the numbers of CD45 high CD11b ϩ cells in the inflamed spinal cord after EAE induction was observed ( Figure 5A ). In addition, we studied the recruitment of different leukocyte subpopulations into the inflamed spinal cord of mice that received platelet-depleting or control serum by performing quantitative PCR analysis for the mRNA of CD4, CD8, and CD11b. On platelet depletion, the mRNA levels of CD4, CD8, and CD11b were reduced as compared with mice receiving control serum, implying reduced recruitment of the respective cells to the inflamed spinal cord (Online Figure IV) . Moreover, the level of granulocytes was significantly reduced after platelet depletion, as assessed by ELISA for myeloperoxidase (Online Figure IV) . That platelet depletion expectedly resulted in reduced platelet accumulation in the inflamed CNS was demonstrated by the marked decrease in platelet-specific GPIb mRNA in the inflamed CNS of mice receiving the platelet-depleting serum as compared with the control serum (data not shown).
To substantiate the impact of platelets on leukocyte recruitment to the inflamed CNS in vivo, we induced EAE in mice and assessed the effect of platelet depletion on leukocyte recruitment to the CNS by spinning disc intravital microscopy. 15, 37 Fourteen days after EAE immunization mice were treated without or with the platelet-depleting reagent and 24 hours thereafter, leukocyte recruitment to the inflamed CNS was assessed by intravital microscopy. A 70% and 50% reduction in the number of rolling leukocytes and of firmly To test the impact of platelets on EAE pathogenesis, EAE was induced in wild-type mice; on days 2 and 6 after induction, mice were treated with control serum (control) or with plateletdepleting serum (Plt depletion) and clinical disease score was assessed (nϭ10 mice per group). B, EAE was induced in wildtype mice; on days 12 and 16 after induction (indicated by arrows), mice were treated with control serum (control) or with platelet-depleting serum and the clinical disease score was assessed (nϭ15 mice per group). *PϽ0.05 as compared with the control group on the same day. adherent leukocytes, respectively, was observed in the vessels of the inflamed CNS of thrombocytopenic mice, as compared with control mice ( Figure 5B through 5D and Online Videos I and II). In the absence of EAE disease, there was virtually no leukocyte adhesion to the vessel wall independent of whether or not platelets were depleted (Online Table II) .
Together, these findings suggest that platelets substantially contribute to EAE disease severity in mice by mediating the overall inflammatory response in the course of EAE, through promoting leukocyte recruitment to the inflamed spinal cord, and the upregulation of multiple inflammatory cytokines, chemokines, and adhesion molecules.
Targeting Platelet GPIb␣ Ameliorates EAE in Mice
Our findings thus far demonstrated that platelets are present in the inflamed CNS tissue after EAE induction and contribute to disease severity by promoting the inflammatory response, including inflammatory cell recruitment to the inflamed CNS. We therefore addressed next whether targeting specific platelet receptors could represent a therapeutic approach in EAE. Platelet GPIb␣ is a component of the GPIb/IX/V complex that interacts with vWF-mediating platelet interactions with the vessel wall and thereby platelet recruitment-, 14 and contributes to inflammatory actions of platelets in part due to its propensity to bind to leukocyte integrin Mac-1 and promote leukocyte/platelet adhesion and leukocyte recruitment. 26 We therefore engaged reagents blocking GPIb␣ in EAE. First, we used a blocking Fab to GPIb␣ that is capable of blocking platelet-vessel wall interactions and thus platelet accumulation. 38 To evaluate the therapeutic potential of GPIb␣ blockade in EAE, we treated mice with the blocking Fab to platelet GPIb␣ at the beginning of the effector phase of the disease, on days 12, 14, and 16, and found a prolonged amelioration of EAE ( Figure 6A ). In the human disease setting, treatment is given after diagnosis of the disease. To mimic this situation, we also treated mice with the blocking Fab to platelet GPIb␣ on days 15, 17, and 19, that is, after the clinical onset of disease. Strikingly, treatment of mice with the Fab to GPIb␣ after disease onset resulted in a transient but significant clinical recovery from EAE, as compared with Fab control treatment ( Figure 6B ). Second, we engaged the antibody anti-M2 that was raised against the binding site of Mac-1 for GPIb␣ and specifically blocks this interaction and thereby platelet-dependent inflammatory cell recruitment. 39 -41 Anti-M2 antibody blocked the adhesion of primary bone marrow-derived macrophages 42, 43 to immobilized surface-adherent platelets 44, 45 in vitro (Online Figure V) , without affecting further Mac-1-dependent adhesive interactions, for example, to fibrinogen or ICAM-1 (Online Figure V) , as previously described. 39 -41 Treatment with antibody anti-M2 on days 12, 14, and 16 resulted in a significant and prolonged reduction of clinical EAE symptoms as compared with control antibody ( Figure 6C ). When the blocking Fab to GPIb␣ was used in combination with the antibody anti-M2, no additive inhibitory effect was observed, indicating that both reagents interfere with the same pathway of platelet-mediated inflammation in EAE (Online Figure VI) .
To assess whether the function of platelets in EAE can be solely attributed to GPIb or the GPIb-Mac-1 interaction molecularly, we engaged an inhibitor of the major platelet adhesive receptor GPIIbIIIa. Blocking Fab to GPIIbIIIa provided a significant reduction in EAE disease severity (Figure 7 ). Together, these data demonstrate that targeting platelet GPIb␣ or other platelet receptors, such as GPIIbIIIa, could represent a specific therapeutic strategy for EAE treatment.
Discussion
The inflammatory response is a major component of MS pathogenesis and thus an important therapeutic target. We demonstrated unequivocally that platelets contribute substantially to the inflammatory response and pathogenesis of EAE and provide clear evidence that targeting platelets is a novel therapeutic strategy in EAE and thereby potentially in human MS.
Previous reports have shown the message of the plateletspecific receptor CD41 (␣ IIb -integrin, GPIIb) in chronic lesions of patients with multiple sclerosis, 28 the presence of platelets in murine neuroinflammation, 46 as well as the relevance of platelet-derived interleukin-1␣ for cerebrovascular inflammation. 47 A recent study has demonstrated increased levels of platelet activation in the peripheral blood of MS patients. 29 Consistently, we were able to demonstrate that platelets are present in the inflamed vessels and the inflamed parenchyma of the CNS during EAE in mice; in addition, platelets were detected by immunohistology in human chronic active MS lesions.
EAE is a chronic inflammatory disease of the nervous system associated with destruction of myelin sheaths and axonal damage. 48 -50 The myelin sheath damage is mediated by the inflammatory response, including recruited inflammatory cells, a process facilitated by the disruption of the BBB. 1 Recruited monocytes/macrophages participate in the phagocytosis of myelin and secrete proinflammatory cytokines. 11 Our experiments using platelet depletion in the course of EAE demonstrated unequivocally that platelets contribute substantially to the inflammatory cell recruitment and thereby to the exacerbation of EAE disease severity. Platelet depletion Figure 5 . Role of platelets for leukocyte recruitment to the inflamed CNS in mice. A, EAE was induced in wild-type mice; on days 12 and 16 after induction, mice were treated with control serum (control) or with platelet-depleting serum. Spinal cord tissue from wild-type mice treated with control serum (control) or with platelet-depleting serum was then collected after extensive systemic perfusion with saline on day 21 after immunization, and leukocytes were isolated with Percoll gradient centrifugation and analyzed by flow cytometry. The number of CD45 high CD11b ϩ cells per spinal cord is shown. Data are meanϮSEM (nϭ4 -5 mice per group). *PϽ0.05. B, C, and D, To test for the impact of platelets on leukocyte recruitment to the inflamed CNS, EAE was induced in wild-type mice; after 2 weeks, mice were treated without (control) or with platelet-depleting serum. Twenty-four hours thereafter, the number of labeled rolling (B) or firmly adherent (C) leukocytes to postcapillary venules was determined using spinning disc intravital microscopy. Data are meanϮSEM and are shown as number of rolling leukocytes per minute or number of adherent leukocytes/100 m (nϭ3-4 mice per group). *PϽ0.05 as compared with control. D, Representative offline images of intravital microscopy experiments showing adherent leukocytes in control mice (left panel) or in mice after platelet depletion (right panel). Scale bar: 100 m.
suppressed EAE when applied in the effector phase of the disease, whereas platelet depletion during the immunization phase did not influence EAE disease induction. These data point to a role of platelets in the inflammatory phase of EAE and in EAE disease exacerbation rather than in EAE disease induction.
Platelets may aggravate inflammation in EAE because they are capable of enhancing monocyte adhesion to endothelial cells. 51 Alternatively, platelets could locally secrete proinflammatory mediators, 16 activating recruited inflammatory cells or resident microglia. As pointed out by our mRNA microarray analysis of inflamed spinal cords, the inflammatory response was blunted in the absence of platelets. Different proinflammatory factors including chemokines, cytokines, and endothelial adhesion molecules were reduced in the spinal cords of mice that received the platelet-depleting serum. It is likely that these different pathways are interconnected with each other, which merits further investigation.
We also demonstrated that the platelet adhesion receptor GPIb␣ may represent a therapeutic target in EAE and MS. Platelet GPIb␣ mediates both platelet-vessel wall interactions and platelet accumulation as well as platelet-dependent leukocyte recruitment. Blocking Fab to GPIb␣ as well as an antibody that specifically interferes with the interaction of GPIb␣ with leukocyte Mac-1 suppressed EAE in mice. This is in accordance with previous findings that blocking antibodies to Mac-1 ameliorated clinical severity of EAE in mice without affecting the number of sick animals, 52 whereas EAE development was reduced in Mac-1Ϫ/Ϫ mice. 53 However, the inhibitory effect on EAE mediated by blocking platelet GPIb␣ is not restricted to the GPIb/Mac-1 interaction. Presumably, alternative GPIb-mediated pathways, such as platelet adhesion to vWF, 17, 54 may participate in the function of platelets in EAE, which should be addressed in future studies. Moreover, blockade of another platelet adhesion receptor, GPIIbIIIa, also reduced EAE disease severity. Thus, the contribution of platelets to EAE is probably multifaceted. We think that strategies to interfere with platelet accumulation and platelet-leukocyte interactions, for example, by targeting GPIb␣, GPIIbIIIa, as shown here, or other platelet adhesion receptor systems, such as the interaction between P-selectin and its ligand on leukocytes, P-selectin glycoprotein ligand-1, might represent therapeutic approaches in EAE and MS. Besides the engaged model for primary progressive EAE disease (in the present study), which reflects a disease subtype of human MS, there is also a relapsing-remitting mouse model, 55 representing a more common MS subtype. The effect of platelets should be studied in relapsing- remitting EAE in future investigations to further substantiate the therapeutic potential of platelet-targeting therapies in MS.
Finally, a recent study demonstrated the crosstalk between coagulation and brain inflammation. In this study, a proteomic approach identified tissue factor and protein C inhibitor within chronic active lesions, and thrombin inhibition was used to reduce EAE severity. 56 Our present data underline this connection between coagulation, platelets, and neuroinflammation and suggest that targeting platelets and their receptors may represent a novel attractive therapeutic approach to ameliorate the inflammatory response in MS.
Novelty and Significance
What Is Known?
• mRNA of platelet-specific genes is upregulated in human chronic multiple sclerosis (MS) lesions.
• Platelets in peripheral blood of patients with MS are in an activated state.
What New Information Does This Article Contribute?
• Platelets accumulate in inflamed lesions of the CNS in the course of experimental autoimmune encephalomyelitis (EAE) in mice, a mouse model for human MS.
• Platelets significantly contribute to the inflammatory response in the effector phase of EAE.
• Platelet depletion or targeting platelet adhesion receptors, such as GPIb␣, ameliorates EAE disease severity.
MS is a devastating disease associated with severe impairment and high mortality. MS and its mouse model EAE are characterized by the infiltration of inflammatory cells into the CNS, mediating tissue damage. Emerging evidence suggests that platelets may be critical contributors of inflammatory cell recruitment. However, little was known about the functional role of platelets in EAE and MS. We present evidence supporting the notion that platelets contribute to the inflammatory response and disease severity of EAE. We demonstrate that platelets are present in the inflamed spinal cord tissue in the course of EAE as well as in human MS lesions. Platelets play a crucial role for leukocyte recruitment to the inflamed CNS. Platelet depletion ameliorated EAE in mice and blunted inflammatory response, whereas the induction of the disease was not affected. Interfering with platelet GPIb␣ or the Mac-1/GPIb␣ interaction attenuated EAE in mice. Therefore, platelets represent an important new therapeutic target in MS. 
Supplemental Material
Intravital microscopy after EAE induction
Animals were anesthetized by i.p. injection of a mixture of 10 mg/kg xylazine and 200 mg/kg ketamine hydrochloride. A cranial window was made using a high-speed drill (Fine Science Tools) and the dura mater was removed to expose the underlying cerebral microcirculation. To observe leukocyte rolling and adhesion, tail vein was cannulated and Rhodamine 6G (0.5 mg/kg body weight) was injected i.v.. Leukocyte endothelial interactions were visualized using BX51W1 spin disk confocal microscope (Olympus, Canada). Three different postcapillary venules with a diameter between 30 and 70 µm were chosen for observation. Throughout the experiment, rectal temperature was continuously monitored and kept at 36°C to 37°C with a heating pad (Fine Science Tools). All experiments were recorded for later playback analysis. Rolling leukocytes were defined as those cells moving at a velocity less than that of erythrocytes. Cells were considered adherent if they remained stationary for at least 30 s. For platelet depletion, mice were pretreated intraperitoneally with rabbit anti-mouse thrombocyte serum (0.5 ml/kg body weight, Accurate Chemical and Scientific Corp.). Four hours before intravital microscopy, this procedure depleted over 97% of platelets from the circulation (data not shown).
Isolation of primary mouse cells
Bone marrow-derived macrophage isolation and murine platelet isolation were performed as described before.
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Adhesion assays
To evaluate the adhesion of primary bone marrow-derived macrophages to platelets, isolated platelets (1x10 7 /well) were allowed to adhere to 96-well plates overnight followed by blocking with BSA (3%). Macrophages (2x10 4 cells/well) were added to the wells and incubated for 40 min. After washing twice with PBS, adherent cells were counted by direct phase contrast microscopy. Adhesion of macrophages to platelets was studied in the absence or presence of anti-M2 antibody specifically raised against the binding site of Mac-1 to GPIb. 6 Similarly, adhesion of mouse macrophages was tested to immobilized fibrinogen (10 g/ml, Molecular Probes) or ICAM-1 (10 g/ml, R&D Systems) without or with anti-M2 (10 g/ml) or IgG control (10 g/ml, rabbit IgG, Dako).
Reverse transcriptase-PCR and real-time RT-PCR.
Total RNA was isolated from spinal cord tissue as described before. 12 Briefly, total RNA was prepared using a Trizol based RNA preparation protocol. Reverse transcription of the RNA was performed using ImProm-II reverse transcription system (Promega) and subsequently the RT-generated cDNA samples were subjected to real-time PCR amplification using an ABI Prism 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA) and a QuantiTect SYBR Green PCR kit (Qiagen, Valencia, CA). Primers were designed using the Primer .
RNA isolation and microarray analysis
The spinal cords of mice subjected to EAE that received the control or platelet depleting serum were collected after transcardiac perfusion. Total RNA was isolated using Trizol reagent (Invitrogen) according to the standard protocol and used to generate biotin-labeled complementary RNA using the Illumina TotalPrep RNA Amplification Kit (Ambion, Austin, TX). For hybridization, the labeled nucleic acid made from total RNA was subjected to Mouse Ref-8 beadchips containing > 24,000
Ref sequences per array (Illumina, Inc., San Diego, CA). Microarray data were analyzed using DIANE 6.0. ANOVA tests were done to eliminate the genes with larger variances within each comparing group. Genes were determined to be differentially expressed after calculating the Z ratio, which indicates the folddifference between experimental groups, and false discovery rate (fdr), which controls for the expected proportion of false rejected hypotheses. Individual genes with p value <=0.05, absolute value of Z ratio >=1.5 or <=-1.5 and fdr <= 0.3 were considered significantly changed. The same cutoff criteria are applied for Gene Ontology (GO) selection (Analysis of microarray data using Z score transformation 15 ).
Detection of platelets in human MS tissue
The MS plaque depicted in Online Figure I is from a patient previously reported in an earlier study. 16 Slides were rehydrated with dH2O overnight at 4°C and equilibrated in phosphatebuffered saline (PBS). Confocal immunofluorescent microscopy was performed as previously described 16, 18 . Briefly, tissues were permeabilized with 0.2% Triton X-100 in PBS and blocked with Image-It FX signal enhancer solution (Molecular Probes, Eugene, OR). To detect platelets, purified monoclonal mouse antibody against human CD42b (BD Biosciences) (1:800 dilution) was utilized. The primary antibody was incubated overnight in a humidified chamber at 4°C. Thereafter, the secondary donkey anti-mouse IgG specific for both heavy and light chains 
Data presentation and statistics
Comparisons between group means were performed using Student t-test or MannWhitney-U analysis as appropriate. P<0.05 was considered statistically significant. 
Online Video I.
To test for the impact of platelets on leukocyte recruitment to the inflamed CNS, EAE was induced in WT mice, after 2 weeks mice were treated with platelet-depleting serum and 24 h thereafter intravital microscopy was carried out. The video sequence is taken from one experiment representative for the experiments described in figure   5B-D) .
Online Video II.
Similarly to supplemental Video 2, EAE was induced in WT mice, after 2 weeks mice were treated with control serum and 24 h thereafter intravital microscopy was carried out. 
